PF-514273

PF-514273
Identifiers
	IUPAC name 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one;
CAS Number	851728-60-4 ;
PubChem CID	11316919;
ChemSpider	9491886 ;
CompTox Dashboard (EPA)	DTXSID80462142 ;
Chemical and physical data
Formula	C21H17Cl2F2N3O2
Molar mass	452.281 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1N(CC(F)(C)F)CCOc2c1nn(c2-c(cc4)ccc4Cl)-c3ccccc3Cl;
	InChI InChI=1S/C21H17Cl2F2N3O2/c1-21(24,25)12-27-10-11-30-19-17(20(27)29)26-28(16-5-3-2-4-15(16)23)18(19)13-6-8-14(22)9-7-13/h2-9H,10-12H2,1H3; Key:FJMQJSUOOGOWBD-UHFFFAOYSA-N;
(what is this?)

PF-514273 is a drug developed by Pfizer, which acts as an extremely selective antagonist for the CB₁ receptor, with approximately 10,000x selectivity over the closely related CB₂ receptor. This very high selectivity makes it useful for scientific research into these receptors, as many commonly used cannabinoid receptor antagonists also block the CB₂ receptor to some extent.[1]

References

Dow RL, Carpino PA, Hadcock JR, Black SC, Iredale PA, DaSilva-Jardine P, et al. (May 2009). "Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity". Journal of Medicinal Chemistry. 52 (9): 2652–5. doi:10.1021/jm900255t. PMID 19351113.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid19351113-1] Dow RL, Carpino PA, Hadcock JR, Black SC, Iredale PA, DaSilva-Jardine P, et al. (May 2009). "Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity". Journal of Medicinal Chemistry. 52 (9): 2652–5. doi:10.1021/jm900255t. PMID 19351113.